Magic mushroom compound probed as brain tool against opioid addiction
NCT ID NCT06810310
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at how psilocybin, the active ingredient in magic mushrooms, affects brain circuits linked to motivation and self-control in people with opioid use disorder. Twenty-four adults in the Philadelphia area will receive either a low or high dose of psilocybin, then undergo brain scans and behavioral tests. The goal is to understand brain changes that might help prevent relapse, not to test psilocybin as a direct treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (PEX010)
What this could lead to
If successful, this study could reveal how psilocybin affects brain pathways tied to addiction, pointing toward new ways to support recovery from opioid use disorder.
What could go wrong
This is a small, early-phase study with only 24 participants, focused on brain imaging rather than clinical outcomes. Results may not lead to a treatment or apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact